AGIO Agios Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AGIO

Price (delayed)

$22.55

Market cap

$1.24B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.35

Enterprise value

$1.25B

Agios is focused on discovering and developing novel investigational medicines to treat malignant hematology, solid tumors and rare genetic diseases through scientific leadership in the field of cellular metabolism. In ...

Highlights
The debt has declined by 9% year-on-year and by 2.6% since the previous quarter
The quick ratio is up by 19% since the previous quarter but it is down by 16% year-on-year
AGIO's net income has shrunk by 123% YoY and by 123% QoQ
Agios Pharmaceuticals's EPS has shrunk by 123% YoY and by 120% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.agios.com
Peers: XNCR EXEL BMRN PFE

Key stats

What are the main financial stats of AGIO
Market
Shares outstanding
54.79M
Market cap
$1.24B
Enterprise value
$1.25B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.02
Price to sales (P/S)
1,478.64
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,502.49
Earnings
Revenue
$832,000
EBIT
-$364.29M
EBITDA
-$345.5M
Free cash flow
-$298.61M
Per share
EPS
-$5.35
Free cash flow per share
-$5.47
Book value per share
$22.1
Revenue per share
$0.02
TBVPS
$24.49
Balance sheet
Total assets
$1.34B
Total liabilities
$128.41M
Debt
$94.61M
Equity
$1.21B
Working capital
$929.35M
Liquidity
Debt to equity
0.08
Current ratio
21.3
Quick ratio
20.3
Net debt/EBITDA
-0.04
Margins
EBITDA margin
-41,526.1%
Gross margin
59.3%
Net margin
-43,796.2%
Operating margin
-45,553.2%
Efficiency
Return on assets
-23.5%
Return on equity
-26%
Return on invested capital
-31%
Return on capital employed
-28.2%
Return on sales
-43,785.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AGIO stock price

How has the Agios Pharmaceuticals stock price performed over time
Intraday
5.97%
1 week
25.49%
1 month
15.82%
1 year
-60.15%
YTD
-31.4%
QTD
-22.54%

Financial performance

How have Agios Pharmaceuticals's revenue and profit performed over time
Revenue
$832,000
Gross profit
$493,000
Operating income
-$379M
Net income
-$364.38M
Gross margin
59.3%
Net margin
-43,796.2%
AGIO's net income has shrunk by 123% YoY and by 123% QoQ
Agios Pharmaceuticals's operating income has decreased by 11% YoY

Growth

What is Agios Pharmaceuticals's growth rate over time

Valuation

What is Agios Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.02
P/S
1,478.64
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,502.49
Agios Pharmaceuticals's EPS has shrunk by 123% YoY and by 120% QoQ
The P/B is 79% below the 5-year quarterly average of 4.6 and 44% below the last 4 quarters average of 1.7
Agios Pharmaceuticals's equity has decreased by 47% YoY and by 7% QoQ

Efficiency

How efficient is Agios Pharmaceuticals business performance
The ROA has plunged by 127% from the previous quarter and by 119% YoY
AGIO's return on equity has dropped by 127% since the previous quarter and by 115% year-on-year
The company's return on invested capital has shrunk by 119% QoQ and by 117% YoY

Dividends

What is AGIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AGIO.

Financial health

How did Agios Pharmaceuticals financials performed over time
The total assets has declined by 46% year-on-year and by 7% since the previous quarter
The total liabilities has declined by 33% year-on-year and by 12% since the previous quarter
The debt is 92% smaller than the equity
The debt to equity has soared by 60% YoY
Agios Pharmaceuticals's equity has decreased by 47% YoY and by 7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.